Coagulation profiles of unexpected DCDD donors do not indicate a role for exogenous fibrinolysis

Am J Transplant. 2015 Mar;15(3):764-71. doi: 10.1111/ajt.13058. Epub 2015 Feb 5.

Abstract

It has been suggested that vascular stasis during cardio-circulatory arrest leads to the formation of microvascular thrombi and the viability of organs arising from donation after circulatory determination of death (DCDD) donors may be improved through the application of fibrinolytic therapy. Our aim was to comprehensively study the coagulation profiles of Maastricht category II DCDD donors in order to determine the presence of coagulation abnormalities that could benefit from fibrinolytic therapy. Whole blood from potential DCDD donors suffering out-of-hospital cardiac arrest was sampled after declaration of death in the emergency department, and rotational thromboelastomeric analysis was performed. Between July 2012 and December 2013, samples from 33 potential DCDD donors were analyzed. All patients demonstrated hyperfibrinolysis (HF), as reflected by maximum clot lysis of 98-100% in all cases, indicating that there is no role for additional fibrinolytic therapy in this setting. As well, we observed correlations between thromboelastomeric lysis parameters and maximum hepatic transaminase levels measured in potential donors and renal artery flows measured during ex situ hypothermic oxygenated machine perfusion, indicating that further studies on the utility of thromboelastometry to evaluate organ injury and perhaps even viability in unexpected DCDD may be warranted.

Keywords: Clinical research/practice; donors and donation: donation after circulatory death (DCD); kidney transplantation/nephrology; liver transplantation/hepatology; organ acceptance; organ procurement; organ procurement and allocation; thrombolytic therapy/thrombolysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Circulation
  • Blood Coagulation*
  • Female
  • Fibrinolysis*
  • Humans
  • Male
  • Middle Aged
  • Organ Transplantation*
  • Tissue Donors*
  • Treatment Outcome